in which Sanofi and Novo Nordisk have eclipsed Lilly, a pioneer in the field. The list price of Basaglar will be $316.85 for a pack of five pens, 15% below the list price of Lantus. The companies ...

But it looks unlikely that Lilly will be able to maintain this with the launch of Humalog, which is available in vial form or as a disposable pen ... version of Sanofi’s Lantus (insulin glargine).

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...